
This is the author’s final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

[http://eprints.gla.ac.uk/138796/](http://eprints.gla.ac.uk/138796/)

Deposited on: 27 March 2017
Clinical characteristics of unknown symptom onset stroke patients with and without DWI-FLAIR mismatch

Götz Thomalla, MD¹, Florent Boutitie, PhD², Jochen B. Fiebach, MD³, Claus Z. Simonsen, MD, PhD⁴, Salvador Pedraza, MD⁵, Robin Lemmens, MD⁶, Norbert Nighoghossian, MD⁷, Pascal Roy, MD², Keith W. Muir, MD⁶, Martin Ebinger, MD³,⁹, Ian Ford, PhD¹⁰, Bastian Cheng, MD¹, Ivana Galinovic, MD³, Tae-Hee Cho, MD⁷, Josep Puig⁵, MD, Vincent Thijs¹¹, MD, Matthias Endres, MD³,⁹, Jens Fiehler, MD¹², Christian Gerloff, MD¹

¹ Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
² Hospices Civils de Lyon, Service de Biostatistique, F-69003 Lyon, France; Université Lyon 1, F-69100 Villeurbanne, France; CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, F-69100 Villeurbanne, France
³ Centrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, Germany
⁴ Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
⁵ Department of Neurology, Hospices Civils de Lyon, Lyon, France
⁶ Department of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, Spain
⁷ KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), B-3000 Leuven, Belgium; VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, B-3000 Leuven, Belgium; University Hospitals Leuven, Department of Neurology, B-3000 Leuven, Belgium
⁸ Institute of Neuroscience & Psychology, University of Glasgow, Glasgow, UK
⁹ Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Berlin, Germany
¹⁰ Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
¹¹ Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, and Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
¹² Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Diagnostikzentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Cover title

Clinical characteristics of DWI-FLAIR-mismatch

Word count

Abstract: 203
Text: 1,677
Tables: 1
Figures: 1
References: 17

Key words: Acute, Ischemic stroke, MRI, Clinical trial, Diffusion weighted imaging, Fluid attenuated inversion recovery imaging, DWI-FLAIR-mismatch, WAKE-UP
Abstract

**Background** – DWI-FLAIR mismatch was suggested to identify stroke patients with unknown time of symptom onset likely to be within the time window for thrombolysis.

**Aims** – We aimed to study clinical characteristics associated with DWI-FLAIR mismatch in patients with unknown onset stroke.

**Methods** – We analysed baseline MRI and clinical data from patients with acute ischemic stroke proven by DWI from WAKE-UP, an investigator-initiated, randomised, placebo-controlled trial of MRI based thrombolysis in stroke patients with unknown time of symptom onset. Clinical characteristics were compared between patients with and without DWI-FLAIR mismatch.

**Results** – Of 699 patients included, 418 (59.8%) presented with DWI-FLAIR mismatch. A shorter delay between last seen well and symptom recognition (p=0.0063), a shorter delay between symptom recognition and arrival at hospital (p=0.0025), history of atrial fibrillation (p=0.19) were predictors of DWI-FLAIR mismatch in multivariate analysis.

All other characteristics were comparable between groups.

**Conclusions** – There are only minor differences in measured clinical characteristics between unknown symptom onset stroke patients with and without DWI-FLAIR mismatch. DWI-FLAIR mismatch as an indicator of stroke onset within 4.5 hours shows no relevant association with commonly collected clinical characteristics of stroke patients.

INTRODUCTION

Information on the time of symptom onset plays a critical role in acute stroke treatment. Intravenous thrombolysis is approved for treatment within 4.5 hours of symptom onset, and for mechanical thrombectomy unequivocal evidence is also only available for treatment within the first six hours (1). In about 20% of acute stroke patients however, information on time of symptom onset is not available, e.g. because of patients waking up with stroke symptoms (2).

Stroke MRI with diffusion weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging has been suggested as biomarker of ischemic lesion age (3). The DWI-FLAIR mismatch, i.e. an acute ischemic lesion visible on DWI without corresponding parenchymal hyperintensity on FLAIR, was demonstrated to have a high positive predictive value in identifying patients within 4.5 hours of symptom onset in a multicentre study (4) as well as in several single centre studies from different groups (5-7). Case series using DWI-FLAIR mismatch to guide intravenous thrombolysis or mechanical thrombectomy in unknown onset stroke patients have previously been published (8, 9).

Using DWI-FLAIR mismatch as surrogate marker of lesion age relies on the assumption that time from symptom onset is the only relevant clinical factor influencing parenchymal hyperintensity on FLAIR and thus the presence or absence of DWI-FLAIR mismatch. There is, however, hardly any data on potential clinical confounders of DWI-FLAIR mismatch in patients with unknown time of symptom onset. Thus, we aimed to identify possible clinical factors of influence on DWI-FLAIR mismatch by comparing clinical characteristics between patients with and without DWI-FLAIR mismatch in a large sample of patients with stroke of unknown onset.

METHODS

Study population
We analysed baseline data from the ongoing WAKE-UP trial (Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial; Clinicaltrials.gov identifier NCT01525290; EudraCT No.: 2011-005906-32) (10). In WAKE-UP MRI including DWI and FLAIR is used for screening stroke patients with unknown time of symptom onset, and patients presenting with DWI-FLAIR mismatch are randomized to treatment with intravenous thrombolysis or placebo. For this analysis we included baseline data of patients enrolled since the start of the trial on 22 September 2011 until 01 April 2016 meeting the following criteria: (1) information on symptom recognition and demographic characteristics available; (2) acute ischemic lesion visible on DWI indicating acute cerebral ischemia; (3) judgement of DWI-FLAIR mismatch available; (4) no signs of intracerebral haemorrhage on MRI.

**DWI-FLAIR mismatch judgment**

DWI-FLAIR mismatch was judged by trial investigators according to image analysis standards outlined in the trial protocol and in additional training material. DWI-FLAIR mismatch is defined as the absence of a marked parenchymal hyperintensity in FLAIR in the region of a clearly visible acute DWI lesion, while subtle FLAIR hyperintensities are disregarded (10). Imaging handbooks provide detailed documentation of the imaging criteria and numerous example cases of the application of the imaging criteria in the trial (see figure for examples). All investigators judging brain images in WAKE-UP have completed a software-based image analysis training and passed a certification exam.

**Data analysis**

In order to identify clinical characteristics associated with the presence of DWI-FLAIR mismatch, univariate analysis was performed comparing patients with and without DWI-FLAIR mismatch regarding the following clinical characteristics: age, sex, time between last seen normal and symptom recognition, delay between symptom recognition and hospital
arrival, reason for unknown time of symptom onset, neurological deficit on admission assessed by the National Institutes of Health Stroke Scale (NIHSS), medical history and vascular risk factors, current medication, presence of clinical exclusion criteria for thrombolysis. Fisher’s exact test or the Chi-square test was used for categorical variables, and non-parametric Kruskal-Wallis test was used for continuous variables. P<0.05 was considered significant in exploratory analysis without correction for multiple tests. Additionally, we performed a multivariate analysis using logistic regression model to predict the odd of DWI-FLAIR mismatch including all covariates with a p-value ≤0.15 in univariate analysis. Finally, only parameters with p<0.05 were retained. SAS software, version 9·3 (SAS Institute Inc., Cary, NC) was used for all analyses.

RESULTS

Overall, 699 patients met the inclusion criteria. Of those 418 (59.8%) presented with DWI-FLAIR mismatch and 281 (40.2%) hat no DWI-FLAIR mismatch. Results of group comparison are shown in the table. Patients with DWI-FLAIR mismatch had a shorter delay between last seen well and symptom recognition (median 7.5 vs. 8.0 h, p=0.0030). A history of atrial fibrillation was more frequent in patients with a DWI-FLAIR (10.6% vs. 4.9%, p=0.0098). In multivariate analysis, both shorter delay between last seen well and symptom recognition with odds ratio (OR) 0.94 (95% confidence interval 0.91-0.98) and history of AF with OR 2.36 (1.11-5.02) were retained as significant predictors of DWI-FLAIR mismatch (see table). In addition, delay between symptom recognition and hospital arrival remained a significant predictor with OR 0.74 (0.62-0.90). All other characteristics were comparable between groups.

DISCUSSION

In this sample of acute stroke patients with unknown time of symptom onset, patients with DWI-FLAIR mismatch indicating symptom onset within 4.5 hours were comparable to
patients with no DWI-FLAIR mismatch with regards to the vast majority of clinical
characteristics. There were no differences in age or severity of neurological symptoms
reflected by the NIHSS score. There were also no differences concerning the majority of
vascular risk factors, current medication, or the reason why symptom onset was not known.
Two parameters differed between groups: the delay between last seen well and symptom
recognition was shorter, and history of atrial fibrillation was more frequent in patients with
DWI-FLAIR mismatch.

This is the first analysis of clinical characteristics in a larger group of stroke patients with
unknown time of symptom onset assumed to qualify for reperfusion treatment based on DWI-
FLAIR mismatch, and the results confirm the assumption that DWI-FLAIR mismatch as
surrogate marker of lesion age is not strongly influenced by clinical characteristics of
patients. This is in line with previous studies of DWI-FLAIR mismatch in patients with known
symptom onset. In a large multicentre study, patients with DWI-FLAIR mismatch were
mismatch were older but otherwise comparable to patients without a DWI-FLAIR
mismatch(4). This, however, was discussed as a potential confounding effect of
leukoaraiosis being more frequent with higher age and interacting with the visibility of acute
ischemic lesions on FLAIR in the elderly. In WAKE-UP, severe leukoaraiosis interacting with
the judgement of DWI-FLAIR mismatch is considered an exclusion criterion, which may
obscure the indirect effect of age observed previously.

With regards to the observed differences between the groups, findings have to be interpreted
with caution as they only apply to patients eligible for this analysis which excluded patients
with poor quality of MRI or severe leukoaraiosis precluding proper judgement of DWI-FLAIR
mismatch,. However, the association of DWI-FLAIR mismatch with shorter delays between
last seen well and symptom recognition and between symptom recognition and hospital
arrival appears biologically plausible considering the visibility of acute ischemic lesions on
FLAIR as a function of time. In all previous studies of DWI-FLAIR mismatch instroke patients
with known onset, shorter time from symptom onset was the strongest predictor of DWI-
FLAIR mismatch (3-7). Although we do not know the time of stroke onset in our patients, it
may be reasonable to assume that a longer delay between last seen normal and symptom recognition may to a certain extent correlate with a longer delay between stroke onset and symptom recognition.

The higher rate of atrial fibrillation in patients with DWI-FLAIR mismatch is less easily explained and may simply be due to chance. On the other hand, a circadian variation of atrial fibrillation with peak incidence in the morning hours (11) is known, and there are observations of a higher frequency of atrial fibrillation in wake-up stroke (12, 13). This might provide an explanation for a higher frequency of atrial fibrillation in those patients from our sample with stroke onset in the morning hours shortly before symptom recognition and thus more likely to show DWI-FLAIR mismatch. On the other hand, rates of atrial fibrillation were comparable between patients with wake-up stroke and those with unwitnessed daytime-onset stroke (8.5% vs. 7.0%, p=0.16 Fisher’s exact test).

Previous case series have reported on the rates of DWI-FLAIR mismatch in smaller samples with stroke of unclear onset as compared to patients with stroke of known onset, but they did not report on clinical characteristics of patients with DWI-FLAIR mismatch as compared to those without (14, 15). The proportion of patients with DWI-FLAIR mismatch in our population was slightly higher than in these two previous studies (59.8% as compared to 43.7% and 50.0%), which may result from the fact that in within the context of WAKE-UP being a thrombolysis trial MRI may have been performed more rapidly, and that patients being clearly beyond the time window for thrombolysis, e.g. because of admission to hospital >4.5 hours of symptom recognition, were a priori excluded. The decreasing rate of DWI-FLAIR mismatch with time passing appears to parallel decreasing proportions of patients with penumbral pattern with time from stroke onset (16). Although by concept DWI-FLAIR mismatch and penumbral imaging, e.g. perfusion-diffusion mismatch, address a different pathophysiological phenomenon, i.e. lesion age on the one hand and metabolic tissue status on the other hand, both imaging parameters appear to show a certain association independent from time fo stroke onset (17, 18). Future analyses of the subgroup of patients with perfusion MRI available in the WAKE-UP trial may further improve the understanding of
this association. To conclude, the MRI pattern of DWI-FLAIR mismatch was not associated with different clinical characteristics except for a longer delay and more frequent atrial fibrillation in the first 699 patients from our trial of intravenous thrombolysis in stroke with unknown symptom onset. Thus, DWI-FLAIR mismatch as indicator of stroke onset of less than 4.5 hours does not seem to be confounded by clinical characteristics of stroke patients beyond time from symptom onset and appears well suited as a surrogate marker of lesion age in patients with unknown time of symptom onset. The question of efficacy and safety of intravenous thrombolysis in unknown symptom onset stroke patients with DWI-FLAIR mismatch will be answered in the final analysis of the WAKE-UP trial.

**FUNDING**

AUTHOR CONTRIBUTIONS:

Götz Thomalla – study concept and design, acquisition of data, analysis and interpretation of data, study supervision, drafting/revising the manuscript for content

Florent Boutitie – analysis and interpretation of data, drafting/revising the manuscript for content

Jochen B. Fiebach – study concept and design, acquisition of data, drafting/revising the manuscript for content

Claus Z. Simonsen – study concept and design, acquisition of data, drafting/revising the manuscript for content

Norbert Nighoghossian – study concept and design, acquisition of data, drafting/revising the manuscript for content

Salvador Pedraza – study concept and design, acquisition of data, drafting/revising the manuscript for content

Robin Lemmens – acquisition of data, drafting/revising the manuscript for content

Pascal Roy – analysis and interpretation of data, study supervision

Keith W. Muir – study concept and design, acquisition of data, drafting/revising the manuscript for content

Martin Ebinger – study concept and design, acquisition of data, drafting/revising the manuscript for content

Ian Ford – drafting/revising the manuscript for content

Bastian Cheng – study concept and design, acquisition of data

Tae-Hee Cho – acquisition of data, drafting/revising the manuscript for content

Josep Puig – acquisition of data, drafting/revising the manuscript for content

Vincent Thijs – study concept and design, acquisition of data, drafting/revising the manuscript for content

Matthias Endres – acquisition of data, study supervision, drafting/revising the manuscript for content

Jens Fiehler – study concept and design, acquisition of data, drafting/revising the manuscript for content

Christian Gerloff – study concept and design, analysis and interpretation of data, study supervision, drafting/revising the manuscript for content
CONFLICTS OF INTEREST

Götz Thomalla received fees as a consultant or lecture fees from Acandis, Bayer Vital, Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, Daichii Sankyo, GlaxoSmithKline, and Stryker.

Florent Boutitie reports no disclosures.

Jochen B. Fiebach received consulting, lecture, and advisory board fees from Perceptive, BioClinica, Boehringer Ingelheim, Cerevast, Brainomix, and Lundbeck.

Claus Z. Simonsen received lecture fees from Boehringer Ingelheim.

Norbert Nighoghossian reports no disclosures.

Salvador Pedraza received fees as a board member, consultant, or lecturer from Lundbeck and Synarc.

Robin Lemmens – RL is a senior clinical investigator of FWO Flanders.

Pascal Roy reports no disclosures.

Keith W. Muir has received honoraria for speaking from Boehringer Ingelheim and Bayer, and has received consultancy fees from ReNeuron Ltd.

Genzyme and Novartis.

Martin Ebinger reports no disclosures.

Ian Ford reports no disclosures.

Bastian Cheng reports no disclosures.

Tae-Hee Cho reports no disclosures.

Josep Puig reports no disclosures.

Vincent Thijs received honoraria from Astra Zeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, and Pfizer for participation in advisory board meetings.

Matthias Endres received fees from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Ever, Glaxo Smith Kline, MSD, Pfizer, Novartis and Sanofi.

Jens Fiehler received fees as a consultant or lecture fees from Codman, Covidien, Siemens and Stryker.

Christian Gerloff received fees as a consultant or lecture fees from Bayer Vital, Boehringer Ingelheim, EBS technologies, Glaxo Smith Kline, Lundbeck, Pfizer, Sanofi Aventis, Silk Road Medical, and UCB.
REFERENCES


TABLE

Table: Group comparison of clinical characteristics

<table>
<thead>
<tr>
<th></th>
<th>DWI-FLAIR-mismatch (n=418)</th>
<th>No DWI-FLAIR-mismatch (n=281)</th>
<th>Group comparison p-value</th>
<th>Multivariate analysis p-value ‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [years], median (IQR)</td>
<td>68 (59-74)</td>
<td>67 (58-74)</td>
<td>0.39</td>
<td>-</td>
</tr>
<tr>
<td>Sex = female, n (%)</td>
<td>147 (35.2)</td>
<td>117 (41.6)</td>
<td>0.095</td>
<td>0.12</td>
</tr>
<tr>
<td>Reason for unknown time of symptom onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nigh-sleep wake-up stroke</td>
<td>368 (88.0)</td>
<td>240 (85.4)</td>
<td>0.15</td>
<td>0.93</td>
</tr>
<tr>
<td>Daytime unwitnessed stroke</td>
<td>50 (12.0)</td>
<td>41 (14.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delay between last seen well and symptom recognition [h], median (IQR)</td>
<td>7.5 (5.0-9.0)</td>
<td>8.0 (6.0-10.0)</td>
<td>0.0030</td>
<td>0.0063</td>
</tr>
<tr>
<td>Delay between symptom recognition and hospital arrival [h], median (IQR)</td>
<td>1.6 (1.1-2.3)</td>
<td>1.8 (1.1-2.6)</td>
<td>0.11</td>
<td>0.0025</td>
</tr>
<tr>
<td>Medical history / risk factors *</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial hypertension, n (%)</td>
<td>200/415 (48.2)</td>
<td>134/266 (50.4)</td>
<td>0.58</td>
<td>-</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>62/410 (15.1)</td>
<td>45/269 (16.7)</td>
<td>0.59</td>
<td>-</td>
</tr>
<tr>
<td>Hypercholesterolemia, n (%)</td>
<td>120/391 (30.7)</td>
<td>68/259 (26.3)</td>
<td>0.25</td>
<td>-</td>
</tr>
<tr>
<td>Atrial fibrillation, n (%)</td>
<td>43/406 (10.6)</td>
<td>13/266 (4.9)</td>
<td>0.0098</td>
<td>0.019</td>
</tr>
<tr>
<td>Ischemic stroke, n (%)</td>
<td>59/415 (14.2)</td>
<td>26/270 (9.6)</td>
<td>0.077</td>
<td>0.47</td>
</tr>
<tr>
<td>Transient ischemic attack, n (%)</td>
<td>15/409 (3.7)</td>
<td>11/269 (4.1)</td>
<td>0.84</td>
<td>-</td>
</tr>
<tr>
<td>Intracranial haemorrhage, n (%)</td>
<td>0</td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gastrointestinal bleeding, n (%)</td>
<td>6/413 (1.5)</td>
<td>5/270 (1.9)</td>
<td>0.76</td>
<td>-</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoked, n (%)</td>
<td>176/401 (43.9)</td>
<td>98/245 (40.0)</td>
<td>0.25</td>
<td>-</td>
</tr>
<tr>
<td>Ex-smoker, n (%)</td>
<td>108/401 (26.9)</td>
<td>60/245 (24.5)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>117/401 (29.2)</td>
<td>87/245 (35.5)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Current medication *</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiplatelets, n (%)</td>
<td>142/414 (34.1)</td>
<td>72/264 (27.3)</td>
<td>0.063</td>
<td>0.26</td>
</tr>
<tr>
<td>Anticoagulants, n (%)</td>
<td>4/415 (1.0)</td>
<td>2/264 (0.8)</td>
<td>1.00</td>
<td>-</td>
</tr>
<tr>
<td>Antihypertensives, n (%)</td>
<td>199/416 (47.8)</td>
<td>141/264 (53.4)</td>
<td>0.18</td>
<td>-</td>
</tr>
<tr>
<td>Antidiabetics, n (%)</td>
<td>54/416 (13.0)</td>
<td>40/462 (15.2)</td>
<td>0.43</td>
<td>-</td>
</tr>
<tr>
<td>Statins, n (%)</td>
<td>124/415 (30.0)</td>
<td>76/264 (28.8)</td>
<td>0.80</td>
<td>-</td>
</tr>
<tr>
<td>NIHSS on admission, median (IQR)</td>
<td>6 (4-11)</td>
<td>6 (4-12)</td>
<td>0.68</td>
<td>-</td>
</tr>
<tr>
<td>Clinical exclusion criteria for IV-tPA treatment present, n (%)</td>
<td>8 (1.9)</td>
<td>10 (3.6)</td>
<td>0.22</td>
<td>-</td>
</tr>
</tbody>
</table>

* Percentage calculated with reference to number of patients with information available;

† intracerebral haemorrhage, subarachnoid haemorrhage, intraventricular haemorrhage, hemorrhagic transformation;

‡ parameters with p≤0.15 in univariate analysis were entered into multivariate logistic regression model

IQR = interquartile range; NIHSS = National Institutes of Stroke Scale;
FIGURE

Examples of DWI-FLAIR mismatch and No DWI-FLAIR mismatch.

The figure shows three cases from the study sample. For each case, two representative slices of diffusion weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) are shown. (A) DWI-FLAIR mismatch – no parenchymal hyperintensity visible on FLAIR in the region of the acute DWI lesion, patient was randomized; (B) DWI-FLAIR mismatch – subtle parenchymal hyperintensity visible on FLAIR in the region of the acute DWI lesion considered as “negative” FLAIR according to the image judgement criteria in WAKE-UP, thus imaging criteria of DWI-FLAIR mismatch are met, patient was randomized; (C) No DWI-FLAIR mismatch – clear parenchymal hyperintensity visible on FLAIR in the regions of acute DWI lesion, patient was not randomized.